For decades, deferoxamine was the sole effective iron chelator - but its demanding subcutaneous infusion regimen limited real-world adherence. Deferasirox introduced once-daily oral chelation, reshaping clinical practice. This post compares the two.
At a Glance #
| Attribute | Deferasirox | Deferoxamine |
|---|---|---|
| Route | Oral (dispersible / FCT / granules) | Subcutaneous infusion 8-12 h, 5-7 nights/week |
| Dosing frequency | Once daily | Multiple nights weekly |
| Typical dose | 20-40 mg/kg/day (dispersible) | 30-60 mg/kg, 5-7 days/week |
| Excretion | Biliary (faecal) | Renal (urine) |
| Adherence | Generally higher | Historically limited by infusion burden |
| Key toxicities | Renal, hepatic, SCAR, GI | Ophthalmic, auditory, growth effects, infusion-site reactions |
Efficacy #
Pivotal RCTs demonstrated non-inferior LIC reduction for deferasirox at 20-30 mg/kg/day vs deferoxamine. Cardiac iron mobilisation is achievable with both when used at adequate doses and adherence.
Practical Considerations #
- Adherence: a well-tolerated oral regimen usually delivers better real-world outcomes than a perfectly-designed infusion regimen patients skip.
- Pediatric acceptability: dispersible tablets disperse in water/juice - generally acceptable for young patients.
- Emergency / hospital settings: deferoxamine retains a role in acute iron poisoning where IV chelation is needed.
- Renal impairment: deferasirox contraindicated when CrCl < 60 mL/min; deferoxamine depends on renal excretion - different considerations.
Which to Choose? #
Deferasirox is the standard first-line oral chelator in transfusional iron overload. Deferoxamine remains relevant for specific clinical situations (pregnancy in some markets, acute iron poisoning, patients intolerant to oral chelators). Combination therapy is reserved for specialist centres.
DEFRATAJ - WHO-GMP Deferasirox dispersible tablets in 5 strengths. See product information.